High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer

Tomasz M. Beer, Mark Garzotto, Nina M. Katovic

    Research output: Contribution to journalArticlepeer-review

    40 Scopus citations

    Abstract

    Calcitriol acts synergistically with carboplatin in preclinical models of adenocarcinoma of the prostate. The authors sought to test high-dose oral calcitriol in combination with carboplatin in patients with metastatic androgen-independent prostate cancer. Seventeen patients received oral calcitriol (0.5 μg/kg) on day 1 and intravenous carboplatin (AUC 7 or AUC 6 in patients with prior radiation) on day 2, repeated every 4 weeks. PSA response was the primary end point and was defined as a 50% reduction confirmed 4 weeks later. Palliative response (2-point reduction or normalization of pain on the present pain intensity [PPI] scale without increased analgesic consumption) was also examined. One of 17 patients (6%, 95% CI, 0-28) achieved a confirmed PSA response. Four patients (24%, 95% CI, 7-49) had PSA reductions ranging from 24 to 38%. Of the 15 patients with a PPI ≥ 1 point on entry, 3 (18%, 95% CI, 4-48) met criteria for palliative response. Treatment-related toxicity was mild and generally similar to that expected with single-agent carboplatin. Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone.

    Original languageEnglish (US)
    Pages (from-to)535-541
    Number of pages7
    JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
    Volume27
    Issue number5
    DOIs
    StatePublished - Oct 2004

    Keywords

    • Calcitriol
    • Carboplatin
    • Chemotherapy
    • Prostate cancer
    • Vitamin D

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer'. Together they form a unique fingerprint.

    Cite this